Pharmaceuticals and Life Sciences representations include:
  • AbbVie (U.S.), in its $55 billion acquisition of Shire (Ireland) (later withdrawn).
     
  • Alcon (Switzerland), and its independent directors, in its $50.4 billion multistage acquisition by Novartis (Switzerland)—first in Novartis’s purchase of Nestlé’s 77% interest in Alcon and then its subsequent acquisition of the remaining publicly held minority interest in the company.
     
  • Amgen (U.S.), in multiple transactions including its:
    • $13.4 billion pending acquisition of worldwide rights to Otezla® (apremilast) from Celgene Corporation (U.S.) in connection with Celgene’s previously announced merger with Bristol-Myers Squibb (U.S.).
    • $167 million acquisition of Nuevolution (Denmark).
    • modified Dutch auction tender offer for up to $10 billion in value of shares of its common stock.
    • $10.5 billion acquisition of Onyx Pharmaceuticals (U.S.), including on more than $8 billion of related finance matters.
       
  • Bayer (Germany), in multiple transactions including its:
    • $7.6 billion pending sale of its Animal Health business to Elanco Animal Health (U.S.).
    • $66 billion acquisition of Monsanto (U.S.).
    • sale of selected crop science assets to BASF (Germany).
    • $14.2 billion acquisition of the consumer care business of Merck (U.S.).
    • $2.9 billion acquisition of Algeta (Norway).
  • Concordia Healthcare (Canada), in multiple transactions including its:
    • $3.5 billion acquisition of Amdipharm Mercury Limited (U.K.).
    • $1.2 billion acquisition of Covis Pharma (Switzerland) and Covis Injectables (Switzerland).
       
  • Deerfield Management (U.S.) and Athyrium Capital (U.S.), in the out of court restructuring of Pernix Therapeutics (U.S.).
     
  • Dyax (U.S.), in its $5.9 billion acquisition by Shire (Ireland).
     
  • Endo International (Ireland), in its $2.6 billion acquisition of Auxilium Pharmaceuticals (U.S.).
     
  • Idenix Pharmaceuticals (U.S.), in its $3.8 billion acquisition by Merck (U.S.).
     
  • Impax Laboratories (U.S.), in multiple transactions including its:
    • $5.5 billion merger with Amneal Pharmaceuticals (U.S.).
    • acquisition of generic products from Teva (Israel) and affiliates of Allergan (Ireland) and $600 million of debt financing for its acquisition.
       
  • Integra Lifesciences Corporation (U.S.), in connection with $3 billion of bank financing.
     
  • Kite Pharma (U.S.), in its $11.9 billion acquisition by Gilead Sciences (U.S.).
     
  • Merck KGaA (Germany), in its $6.4 billion pending acquisition of Versum Materials (U.S.).
     
  • Oaktree Capital Management (U.S.), in connection with its secured term loan and warrants to OxfordBiomedica, a U.K. public company.
     
  • Perrigo (U.S.), in its $8.6 billion acquisition of Elan Pharmaceuticals (Ireland).
     
  • Praxair (U.S.), in its $80 billion merger of equals with Linde (Germany).
     
  • Seattle Genetics (U.S.), in its $614 million acquisition of Cascadian Therapeutics (U.S.), and related bridge financing.
     
  • Stemcentrx (U.S.), in its $9.8 billion acquisition by AbbVie (U.S.).
     
  • Sprout Pharmaceuticals (U.S.), in its $1 billion acquisition by Valeant Pharmaceuticals (Canada).
     
  • Synageva (U.S.), in its $8.4 billion acquisition by Alexion Pharmaceuticals (U.S.).
     
  • Takeda Pharmaceutical (Japan), on U.S. securities law, in its $62 billion acquisition of Shire (Ireland).
     
  • Teva Pharmaceutical (Israel), in multiple transactions including its:
    • $40.5 billion acquisition of Allergan Generics (Ireland).
    • $50.5 billion withdrawn unsolicited acquisition of Mylan (U.S.).
       
  • Valeant Pharmaceuticals (Canada), in multiple transactions including its:
    • $15.8 billion acquisition of Salix Pharmaceuticals (U.S.).
    • $56 billion unsolicited acquisition of Allergan (U.S.) (later withdrawn).
       
Medtech representations include:
  • CONMED (U.S.) in its $365 million acquisition of Buffalo Filter (U.S.) and $265 million acquisition of SurgiQuest (U.S.).
     
  • Cyberonics (U.S.), in its $1.5 billion merger with Sorin (Italy) to create LivaNova (U.K.).
     
  • Philips (Netherlands), in multiple transactions including its:
    • acquisition of the Healthcare Information Systems business of Carestream Health (U.S.).
    • $2 billion acquisition of The Spectranetics Corporation (U.S.).
    • acquisition of Electrical Geodesics (U.S.).
    • acquisition of Respiratory Technologies (U.S.).
    • acquisition of Wellcentive (U.S.).
    • $1 billion acquisition of Volcano Corporation (U.S.).
       
  • Stryker (U.S.), in multiple transactions including its:
    • $55 million acquisition of Stanmore Implants Worldwide (U.S.) from SIW Holdings (U.K.).
    • $2.8 billion acquisition of Sage Products (U.S.) from Madison Dearborn Partners (U.S.).
    • $764 million acquisition of Trauson Holdings (China).
       
  • Verily Life Sciences (U.S.), an Alphabet (U.S.) company, in its partnership with Temasek (Singapore).

Health Insurer representations include:
  • CVS (U.S.), in multiple transactions including its:
    • $12.7 billion acquisition of Omnicare (U.S.).
    • $2.1 billion acquisition of Coram (U.S.) from Apria Healthcare Group (U.S.).
    • 50/50 joint venture with Cardinal Health (U.S.).
       
  • Medco Health Solutions (U.S.), in its $29.1 billion merger with Express Scripts (U.S.).
     
  • UnitedHealth (U.S.), in multiple transactions including its:
    • $2.8 billion acquisition of Empresas Banmédica (Chile).
    • $4.9 billion acquisition of 90% of Amil Participações (Brazil).
       
Healthcare Services representations include:
  • Ares Management (U.S.), in connection with its managed funds' $1.45 billion strategic partnership with DuPage Medical Group (U.S.) and related financing.
     
  • Genomic Health (U.S.), in its $2.8 billion pending combination with Exact Sciences (U.S.).
     
  • LabCorp (U.S.), in its $6.1 billion acquisition of Covance (U.S.).
     
  • Quality Care Properties (QCP) (U.S.), in its agreement with HCR ManorCare (U.S.) to transition the ownership and leadership of HCR ManorCare, including its skilled nursing, assisted living, hospice and homecare businesses to QCP.
     
  • Syneos Health (U.S.), in its $7.4 billion merger of equals with inVentiv Health (U.S.).
     
  • UnitedHealth (U.S.), in multiple transactions including in connection with:
    • Optum’s (U.S.) $4.3 billion acquisition of DaVita Medical Group (U.S.).
    • its pharmacy care business OptumRx’s (U.S.) $12.8 billion combination with Catamaran Corporation (U.S.).